Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki

We love to hear from our listeners. Send us a message. In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). Dr. Putzki walks us through the six-year development journey behind the STEER and STRENGTH Phase 3 programs. And we explore what the expanded age-range label means for patients who were previously left behind, why intrathecal, fixed-dose AAV delivery represents a pivotal advance for safety, efficacy, and scalability. He details how the Itvisma program is informing Novartis’ broader gene therapy strategy across neuromuscular and CNS diseases, and more.

You can listen to Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki online on Radio and Podcast. Open the player on this page to stream the available audio.

Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki is an episode from Cell & Gene: The Podcast by Erin Harris.

This episode is 21:05 long.

This episode was published on Jan 1, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Cell & Gene: The Podcast when more episodes are available from the podcast feed.